Log in
Forgot password ?
Become a member for free
Sign up
Sign up
Dynamic quotes 

4-Traders Homepage  >  Equities  >  Euronext Paris  >  Sanofi    SAN   FR0000120578

Mes dernières consult.
Most popular
News SummaryMost relevantAll newsSector newsTweets

Sanofi: Tests Show Zaltrap Improves Colorectal Cancer Survival Rate

share with twitter share with LinkedIn share with facebook
share via e-mail
10/08/2012 | 07:44am CEST

French drug company Sanofi SA (>> SANOFI) Monday said results from the pivotal Phase III Velour study evaluating Zaltrap showed improvement in overall survival rate to colorectal cancer.


- Sanofi said the Journal of Clinical Oncology published the results of the study evaluating Zaltrap effects.

- In the Velour trial evaluating metastatic colorectal cancer patients previously treated with an oxaliplatin-containing regimen, Zaltrap in combination with the Folfiri chemotherapy regimen (5-fluorouracil, leucovorin, irinotecan) showed a statistically significant improvement in overall survival, progression-free survival, and the overall tumor response rate versus placebo plus Folfiri.

- The Velour data supported the regulatory approval of Zaltrap by the U.S. Food and Drug Administration (FDA) on August 3, 2012 after a Priority Review.

- Zaltrap is under review at the European Medicines Agency and other regulatory agencies worldwide, Sanofi says.

-Write to Inti Landauro at inti.landauro@dowjones.com

Subscribe to WSJ: http://online.wsj.com?mod=djnwires

Stocks mentioned in the article : SANOFI
share with twitter share with LinkedIn share with facebook
share via e-mail
Latest news on SANOFI
11:38a SANOFI : EpiPen maker finalizes $465 million settlement
10:10a SANOFI AVENTIS PAKISTAN : Board of directors meeting of Sanofi - Aventis Pakista..
08/17 SANOFI : Mylan Agrees to Pay $465 Million to Resolve False Claims Act Liability
08/17 SANOFI : EpiPen maker finalizes settlement for government overcharges
08/17 SANOFI : and Regeneron end ten-year mAb collaboration
08/17 LEXICON PHARMACEUTICALS : builds case for Sanofi-partnered diabetes pill
08/16 INSIDER TRADING ACTIVITY MYOKARDIA, : MYOK) – Major Shareholder Bought 35..
08/16 SANOFI : Regeneron drops RSV drug
08/16 LEXICON PHARMACEUTICALS : With an eye on the FDA, Lexicon and Sanofi line up mor..
08/14 SANOFI : Publishes Its First Integrated Report
More news
News from SeekingAlpha
08/17 House Dems look into MS med prices, seven drug makers contacted
08/15 Tracking Warren Buffett's Berkshire Hathaway Portfolio - Q2 2017 Update
08/14 Fibrogen And Galapagos Raise Lung Disease Hopes
08/11 MyoKardia's Strong Secondary Offering Flashes A Buy Signal
08/11 SANOFI'S ZIKA STANDOFF : Bad Medicine?
Financials (€)
Sales 2017 36 335 M
EBIT 2017 9 499 M
Net income 2017 7 865 M
Debt 2017 4 807 M
Yield 2017 3,68%
P/E ratio 2017 13,44
P/E ratio 2018 17,42
EV / Sales 2017 3,01x
EV / Sales 2018 2,91x
Capitalization 104 481 M
Duration : Period :
Sanofi Technical Analysis Chart | SAN | FR0000120578 | 4-Traders
Technical analysis trends SANOFI
Short TermMid-TermLong Term
Income Statement Evolution
Mean consensus OUTPERFORM
Number of Analysts 27
Average target price 86,0 €
Spread / Average Target 4,0%
EPS Revisions
Olivier Brandicourt Chief Executive Officer & Director
Serge Weinberg Chairman
Jérôme Contamine Chief Financial Officer & EVP-Finance
Elias A. Zerhouni President-Global Research & Development
Yong-Jun Liu Head-Global Research & Development
Sector and Competitors
1st jan.Capitalization (M$)
SANOFI7.62%122 613
JOHNSON & JOHNSON15.48%357 079
ROCHE HOLDING LTD.5.37%218 752
NOVARTIS10.59%218 545
PFIZER1.45%196 221